NCT01050933

Brief Summary

Post operative ileus (POI), a temporary paralysis of the intestines, is a serious health care problem. It normally occurs in all patients after surgery to the abdomen but in some cases can result in serious complications. The objective of this study is to determine if inhaling very low doses of carbon monoxide (CO) before and after colon surgery will shorten the duration of normal POI and/or prevent the development of POI complications in patients undergoing colon surgery. This preliminary study will be conducted in ten healthy volunteers to monitor for blood levels and adverse effects that occur at different durations of exposure of inhaled CO to establish a safe dose for patients in the main trial. For the main trial, patients requiring surgery to their colon will be assigned randomly to receive one hour treatments of either CO or oxygen by face mask before and after their operation. We hypothesize that healthy volunteers will be able to tolerate 1 hour doses of 250 ppm of CO with minimal side effects. It is also anticipated that for each dose of CO administered, the blood levels of CO will remain well under poisonous levels. Finally, we anticipate blood levels of CO will return to baseline level within 24 hours following the last dose of CO.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_1 healthy

Timeline
Completed

Started Sep 2010

Longer than P75 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 13, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 18, 2010

Completed
8 months until next milestone

Study Start

First participant enrolled

September 1, 2010

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
Last Updated

November 17, 2015

Status Verified

November 1, 2015

Enrollment Period

9 months

First QC Date

January 13, 2010

Last Update Submit

November 15, 2015

Conditions

Keywords

Healthy volunteer

Outcome Measures

Primary Outcomes (1)

  • Adverse Event Rate

    Before and after carbon monoxide exposure

Study Arms (1)

Carbon Monoxide

EXPERIMENTAL

Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.

Drug: 250 ppm carbon monoxide

Interventions

250 ppm of inhaled carbon monoxide over one hour

Carbon Monoxide

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women, age \> 18 years.
  • Women must be using acceptable contraceptives, post-menopausal or surgically sterile.
  • No prior smoking history.
  • BMI between 16 and 30 inclusive.
  • In good health as per medical history, physical exam, vital signs \& ECG.

You may not qualify if:

  • Exposure to carbon monoxide during the 48 hours prior to the study day.
  • Occupational exposure to CO.
  • Significant disease that may put the volunteer at risk because of participation in the study or may influence the results of the study or the volunteer's ability to participate in the study.
  • Baseline blood level of COHb \>2%.
  • Patients with underlying lung disease such as asthma or COPD.
  • Baseline oxygen saturation \<92% on room air.
  • Planned pregnancy, already pregnant or breastfeeding.
  • Participation in another clinical trial within 2 months prior to study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kingston General Hospital

Kingston, Ontario, Canada

Location

Study Officials

  • Paul Belliveau, MD

    Queen's University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 13, 2010

First Posted

January 18, 2010

Study Start

September 1, 2010

Primary Completion

June 1, 2011

Study Completion

October 1, 2011

Last Updated

November 17, 2015

Record last verified: 2015-11

Locations